Sign in

    Anna Krasinski

    Vice President and Equity Research Analyst at Barclays

    Anna Krasinski is a Vice President and Equity Research Analyst at Barclays, specializing in European chemicals and materials sectors with coverage of major companies such as BASF, Solvay, and Linde plc. Known for her keen market insight, she has delivered actionable investment research with a success rate above 65% and consistently maintains a strong ranking among peer analysts on platforms like TipRanks. Krasinski began her financial career in 2012 at Credit Suisse before moving to Barclays in 2017, where she rapidly advanced to her current role. She holds FINRA Series 7 and Series 63 registrations and is recognized for her sharp analytical expertise and client-focused achievements within investment research.

    Anna Krasinski's questions to QUEST DIAGNOSTICS (DGX) leadership

    Anna Krasinski's questions to QUEST DIAGNOSTICS (DGX) leadership • Q2 2025

    Question

    Anna Krasinski, on for Luke Sergott at Barclays, asked about the drivers behind the significant step-up in organic volume growth this quarter compared to the prior year's trend and how to think about this metric going forward.

    Answer

    CEO James Davis attributed the strong organic volume growth to several factors: a steady ramp-up in business from new health plan access gained in January, strong uptake in advanced diagnostics, and a rebound from weather-impacted appointments in Q1. He also noted that the employer health and drug testing businesses have stabilized and are no longer a headwind. CFO Sam Samad added that increased requisition density (tests per req) also contributed to strong overall results.

    Ask Fintool Equity Research AI